An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus-Reference-Cited by-同舟云学术

An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus

Published:2021-10-13 Issue: Volume: Page:1-13
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Novodvorský Peter¹²³^ORCID,Haluzík Martin¹⁴

Affiliation:

1. Diabetes Centre, Institute for Clinical and Experimental Medicine (Ikem), Prague, Czech Republic

2. Department of Oncology & Metabolism, University of Sheffield, Sheffield, UK

3. MUDr. Korecová Metabolické Centrum, Trenčín, Slovakia

4. First Faculty of Medicine, Charles University, Prague, Czech Republic

Funder

Czech Republic - conceptual development of research organization („Institute for Clinical and Experimental Medicine

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2021.1978974

Reference81 articles.

1. IDF Diabetes Atlas, 9th edition Brussells, Belgium: International Diabetes Federation; 2019. [cited 2021 Mar 10]. Available from: http://www.diabetesatlas.org

2. Metabolic syndrome: definitions and controversies

3. Prevalence of the Metabolic Syndrome and Its Relation to All-Cause and Cardiovascular Mortality in Nondiabetic European Men and Women

4. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

5. Insulin Resistance, Hyperglycemia, and Atherosclerosis

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparation of fixed‐ratio (IDegLira and iGlarLixi) versus free combination of basal insulin and glucagon‐like peptide‐1 receptor agonist for uncontrolled type 2 diabetes: A systematic review and network meta‐analysis;Journal of Evidence-Based Medicine;2024-06

2. The IDEAL (Insulin therapy DE-intensificAtion with iglarLixi) Randomised Controlled Trial—Study Design and Protocol;Diabetes Therapy;2024-04-24

3. Characterization of Plant-Derived Natural Inhibitors of Dipeptidyl Peptidase-4 as Potential Antidiabetic Agents: A Computational Study;Pharmaceutics;2024-04-01

4. Fixed-ratio Combinations (basal Insulin Plus GLP-1RA) In Type 2 Diabetes. an Analytical Review Of Pivotal Clinical Trials;Review of Diabetic Studies;2023-03-31

5. iGlarLixi (insulin glargine 100 U/ml plus lixisenatide) is effective and well tolerated in people with uncontrolled type 2 diabetes regardless of age: A REALI pooled analysis of prospective real‐world data;Diabetes, Obesity and Metabolism;2023-03-21